Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Titel:
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Auteur:
Reck, Martin Mok, Tony S K Nishio, Makoto Jotte, Robert M Cappuzzo, Federico Orlandi, Francisco Stroyakovskiy, Daniil Nogami, Naoyuki RodrÃguez-Abreu, Delvys Moro-Sibilot, Denis Thomas, Christian A Barlesi, Fabrice Finley, Gene Lee, Anthony Coleman, Shelley Deng, Yu Kowanetz, Marcin Shankar, Geetha Lin, Wei Socinski, Mark A